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Abstract  
Hematopoietic stem cell transplant is an effective treatment and curative therapy for 
many oncological, hematological, and immunological diseases. Following hematopoietic stem 
cell transplant, the management of the prescribed complex treatment regimen may be 
overwhelming for adolescents and young adults and their caregivers, resulting in non-adherence. 
In this patient population, adherence to the daily prescribed treatment regimen is estimated at 33 
to 73%. Non-adherence to a prescribed medication regimen can lead to reduced treatment 
efficacy, resulting in suboptimal clinical outcomes and increased healthcare expenditure. The 
purpose of this evidence-based practice project was to determine if the implementation of 
adherence promoting interventions combined with the MedActionPlan PRO application and 
checklist over 12 weeks fosters treatment adherence and self-management of the prescribed 
medication regimen. Two adolescents and young adults, ages 12 -20 years, who underwent 
hematopoietic stem cell transplant were enrolled with their caregiver through convenience 
sampling from the bone marrow transplant unit in a tertiary care pediatric hospital in the 
Midwest.  The intervention included a multicomponent intervention package and a 
MedActionPlan PRO checklist. The project demonstrated 100 % attendance for adherence-
focused intervention sessions. Medication adherence through self-report from baseline to post-
intervention remained unchanged. One participant showed acceptability for intervention sessions 
as indicated in self-report and endorsed that intervention sessions improved personal 
organization. Both participants reported feasibility and acceptability of the MedActionPlan PRO 
checklist.   
Keywords: pediatric hematopoietic stem cell transplant, adolescents and young adults, 
non- adherence, adherence-focused interventions, MedActionPlan PRO checklist, and self-
management. 
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Medication Adherence in Adolescent and Young Adult after 
 Hematopoietic Stem Cell Transplant 
 Hematopoietic stem cell transplantation (HSCT) has been an increasingly utilized therapy 
for many oncological, hematological, immunological diseases, as well as bone marrow failure 
(McGrady et al., 2014).  The Worldwide Network for Blood and Marrow Transplantation (2013) 
reported that as of 2012 about 1 million people received hematopoietic stem cell transplants 
worldwide which is a significant increase since 2004. Each year approximately 20,000 people 
benefit from hematopoietic stem cell transplants in the United States which includes 3,500 
children, adolescents, and young adults, ranging from infants to 30 years (Health Resources and 
Services Administration, 2015).  
Significance   
Hematopoietic stem cell transplantation is a complex process involving an intense and 
life-threatening treatment regimen (Ezzone, 2013) and carries potential complications such as 
primary disease relapse, infection, and graft versus host disease (Pasquini & Zhu, 2015) with 
overall survival of 50 to 60% (Morrison et al., 2017). Essentially, HSCT recipients require 
effective treatment management and monitoring to prevent potentially life-threatening 
complications. The treatment regimen mainly includes immunosuppressants, prophylactic 
antibacterial and antiviral and antifungal therapy, and electrolyte supplements. The HSCT 
recipients receive these therapies during their inpatient care and continue upon discharge. The 
therapies can become quite cumbersome for the patient and the caregiver, and often result in 
non-adherence (Morrison et al., 2017; Pai et al., 2017).  In general, adolescents and young adults 
(AYAs) are known to be particularly vulnerable and have greater difficulties in adhering to 
treatment schedules due to normative developmental behaviors (Kondryn et al., 2011; Morrison 
et al., 2017). These behaviors are described as achieving independence from parents, adopting a 
MEDICATION ADHERENCE   4 
 
 
 
peer lifestyle, and risk-taking which are interrupted following HSCT (Kondryn et al., 2011; 
Morrison et al., 2017) 
Given the negative ramification of medication adherence, the Center for Disease Control 
(CDC, 2013), the National Institutes for Health (NIH, n.d.), and the World Health Organization 
(WHO, 2003) have recognized adherence as a worldwide problem of striking magnitude, costing 
approximately $300 billion to the United States healthcare system (Pai et al., 2014).  The 
National Institute of Health (NIH, 214) reported that the rate of non-adherence to treatment 
regimen increases over time, from 27% within the first month of discharge to 39 - 74% 
during the three months post-discharge. The non-adherence rate suggests that a substantial 
proportion of AYAs with special health care needs may be receiving sub-therapeutic doses 
of prescribed medications. Considering the prevalence of non-adherence in AYAs and the 
associated negative consequences, non-adherence is recognized as a target for research and 
intervention. Research suggests that multicomponent adherence interventions lead to the greatest 
improvements in medication adherence (Kahana, Drotar, & Frazier, 2008). Also, technology-
based intervention results in improved adherence (Mistry et al., 2015).   
Local Issue 
According to the Center for International Blood and Marrow Transplant Research 
(CIBMTR) Transplant Activity Report from January 2014 – December 2015, participating 
centers in the Midwest include three pediatric hospitals. One of the pediatric hospitals performs 
about sixty-seven pediatric transplants annually, including fifty-two allogeneic and fifteen 
autologous transplants. Another hospital performs about eighteen transplants every year, 
including ten allogeneic and eight autologous transplants. The third pediatric hospital performs 
seventy transplants, and thirty-nine are allogeneic and thirty-one are autologous transplants. The 
CIBMTR from 2014 – 2015 for HSCT indicates that among unrelated donor allogeneic HSCT 
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within the first 100 days that mortality to infection, organ failure, and graft versus host disease 
account for 45% of the deaths. Among matched related sibling transplants within the first 100 
days, the primary disease accounts for 27% of deaths, while infection and organ failure represent 
36% of deaths.   
Diversity Consideration 
Over the past decade, one of the cities with a hospital that performs HSCT in the 
Midwest has experienced significant growth with an estimated population of 481,420 with 51.7% 
of the population as female while 48.2% is male (United States Census Bureau, 2010). The 
current increase in population makes this city the 37th largest city in the United States. Children 
over 5 to 18 years of age comprise 23.5% of the population (United States Census Bureau, 
2010). The city is diverse, representing ethnicities of 60.1% Caucasian, 29.1% African 
American, and 10% Hispanic or Latino (United States Bureau, 2010). The median household 
income is approximately $47,489 with a poverty rate of 18.3% and 9.1% without health 
insurance (United States Census Bureau, 2010). The tertiary academic pediatric institution in this 
city was the site for the evidence-based project. According to a report from the pediatric hospital 
(2015), about 91.6% speak English as their primary language with 7.1% Spanish-speaking.  The 
bone marrow transplant unit receives referrals from this patient demographic and performs about 
35-40 HSCT yearly.   
Problem and Purpose  
In recent literature, suboptimal adherence to treatment regimens is defined as taking less 
than 80% of all prescribed medication (Rapoff, 2010) and is reported across ages, medical 
conditions and prescribed treatment regimen (Kondryn et al., 2010; Sitrratt et al., 2015; Wu et 
al., 2018). The highest incidence of non-adherence is reported among AYAs, resulting in 
morbidity and mortality, suboptimal clinical outcomes, and an increase in healthcare expenditure 
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(Kondryn et al., 2010; Sitrratt et al., 2015; Wu et al., 2018). Hematopoietic stem cell transplant is 
a relatively expensive and lifesaving treatment for many diseases (McGardy et al., 2014). During 
the past decade, there has been a significant increase in the incidence of HSCT recipients. Given 
the impact of HSCT on overall survival rates, the recipients must comply with the prescribed 
treatment regimen to achieve a therapeutic medication effect.  Due to the complex nature of 
treatment adherence, the approach needs to be multifactorial (Pai & McGardy, 2015). Recent 
research suggests that incorporating adherence promoting interventions with technology-based 
intervention can substantially improve adherence to prescribed treatment. The purpose of this 
evidence-based practice project was to improve adherence and daily management of prescribed 
treatment in AYA by using an adherence promoting intervention combined with a 
MedActionPlan PRO application (app) with checklist.  
Facilitators and Barriers 
The facilitator for this project was a licensed psychologist at the project site and received 
her postdoctoral training in the Center for the Promotion of Treatment Adherence and Self-
Management at Cincinnati Children’s Hospital Medical Center. She has substantial experience in 
working with adolescents with chronic illnesses and has applied and tested a multicomponent 
intervention package (MIP) to improve adherence in youth with a chronic medical condition. As 
a facilitator, her ongoing support for this project was significant in the successful implementation 
of MIP in the study population. A barrier to this project was recruiting HSCT recipients ages 12 
to 20 years within the limited timeframe of the study, given the complex process involved during 
pre and post-transplant. Before the transplant, the patients undergo pre-transplant screening. 
They are admitted for HSCT only when pre-transplant lab results are normal and they have 
achieved remission. After HSCT, their discharge is based on recovery and clinical condition 
which may take 3 -4 weeks or longer if they experience post HSCT complications.    
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Review of the Evidence  
Inquiry 
Does the delivery of a multicomponent intervention package and use of MedActionPlan 
PRO app with checklist improve adherence to prescribed medication in AYA hematopoietic stem 
cell recipients during three months at a bone marrow transplant outpatient clinic? 
Literature Search    
A variety of literature search methods were utilized in obtaining evidence-based research 
that supports adherence promoting interventions and technology-based interventions in 
adolescent and young adults with HSCT. The search used the databases of Cumulative Index to 
Nursing and Allied Health Literature (CINAHL), Ovid Medline, PubMed, and Cochrane. Search 
terms included hematopoietic stem cell transplant, transplants, chronic health conditions, 
adolescents, young adults, non- adherence, adherence-focused interventions, technology-based 
interventions, and clinical outcome (see Appendix A). Other sources included national and 
international health organizations such as National Institute of Health (NIH), World Health 
Organization (WHO), National Marrow Donor Program (NMDP), Center for International Blood 
and Marrow Transplant Research (CIBMTR), and the Center for Disease Control (CDC). The 
inclusion criteria for the studies derived from the databases were published in English from 2010 
to current. Twenty studies provided evidence for this project. The search yielded nine articles 
with AYA transplant recipients, adherence barriers, and chronic health conditions including 
cancer.  Eleven articles addressed adherence promoting interventions and technology-based 
interventions. Of these 20 studies, seven were systematic reviews, three were randomized control 
trials, seven were cohort studies, one was a longitudinal study, one was a single descriptive 
study, and one represented a consensus report. The level of evidence (Melnky & Overholt 2015) 
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included seven of level one, three of level two, seven of level four, one of level five, and one of 
level seven evidence (see Appendix B).  
Synthesis of Evidence  
Limited research is available on treatment adherence in the AYA who are HSCT 
recipients. Given the similar trend for medication adherence in AYA cancer and chronic health 
conditions, studies on chronic conditions were included in the synthesis of evidence. Three 
themes that support the inquiry are the a) impact of multicomponent intervention package (MIP) 
in promoting adherence in AYAs, b) utilization of technology-based intervention in enhancing 
treatment adherence in AYAs, and c) recognizing adherence barriers to maximize the impact of 
MIP (see Appendix C).  
 Multicomponent intervention package (MIP) to promote adherence. In a meta-
analysis, Hood and colleagues (2010) studied the effects of adherence promoting interventions to 
improve glycemic control in youth less than 19 years old with diabetes type I. They found that 
improvement in glycemic control was significant in the treatment group compared to the no- 
treatment group. They reported that adherence promoting interventions focus on many facets, 
including treatment regimen and psychosocial aspect of patient and family by educating patients 
and caregivers throughout the process.  These interventions enable patients and caregivers to 
sustain adherence to a treatment regimen for a longer duration.  In another meta-analysis, Pai and 
McGardy (2014) studied youth with chronic health conditions and explored the efficacy of 
adherence enhancing interventions. They reviewed the impact of the implementation of both in-
person and technology-mediated interventions. They concluded that future studies are needed to 
re-examine the effectiveness of these interventions which will dictate treatment adherence 
methodology and potential clinical outcomes in this crucial patient population.  
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Pai and McGardy (2014) conducted a systemic review and meta-analysis assessing 
medication adherence in pediatric oncology and established standard of care for enhancing 
treatment adherence in the study population. Based on their analysis of the literature, they 
recommended standardization of self-reported assessment of adherence by patients and families, 
routine assessment of adherence and education materials on medication, evaluation for 
medication side effects, and assessment for potential implications of non-adherence. They found 
ongoing education, using electronic pill bottles, self-report, and monitoring serum drug levels 
were effective measures for monitoring adherence; however, future studies are warranted for 
intervention effectiveness. Maddux and colleagues (2017) studied adolescents with inflammatory 
bowel disease and examined the effectiveness of a multicomponent intervention package on 
medication adherence. The intervention package was implemented in four weekly sessions, and 
adherence data was collected pre and post-intervention.  The findings indicated that 100% 
attendance was achieved for the intervention sessions, and significantly higher adherence was 
observed from baseline to post-intervention. They concluded that the use of multicomponent 
interventions to enhance treatment adherence is both effective and feasible, particularly when the 
interventions are tailored to the adherence barrier identified by patients and their caregivers.   
 Utilization of technology-based intervention in enhancing treatment adherence. In a 
pilot study, Creary et al. (2014) studied children with sickle cell disease and examined the 
efficacy of mobile electronic directly observed therapy (mDOT) in improving compliance with 
oral hydroxyurea.  The study participants were required to videotape their daily administration 
and ingestion of hydroxyurea. Throughout the study, each participant received electronic 
medication reminders and feedback from the project team member. The study authors reported 
that utilization of mDOT in enhancing compliance with hydroxyurea led to the improvement in 
clinical outcomes of participants. Mistry et al. (2015) conducted a systematic review of 
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randomized clinical trials (RTCs) assessing the effect of technology-mediated intervention (TMI) 
in enhancing patient adherence to prescribed medications and improving clinical outcomes. They 
grouped RTCs into education and counseling, self-monitoring and feedback, and electronic 
reminders. Half of all the studies showed improvement in treatment adherence with TMI and 
more than one-third of all the studies indicated improvement in clinical outcomes. They 
concluded that technology-mediated intervention remains promising for future application to 
improve treatment adherence.  
Shellmer et al. (2016) developed and examined the Teen Pocket Path (TPP), a mobile 
health application, by conducting a prospective study. They used TPP application as an 
intervention to promote treatment adherence and improve adolescent and caregiver 
communication related to treatment management. The goal of the study was to motivate 
adolescents to self-manage their treatment regimen through the TPP approach. They concluded 
that the TPP application has the capability of keeping both the patient and the caregiver involved 
in the daily management of the treatment regimen by preventing non-compliance to the treatment 
schedule. They predicted that the TPP application could be broadly utilized as a future adherence 
tool.  
Badawy and Kuhns (2016) conducted a systematic review to evaluate the cost-
effectiveness of smartphone-based interventions used in improving treatment adherence in youth 
experiencing chronic illnesses. They suggested that because the technology-based interventions 
have shown beneficial evidence-based implications, they should be utilized to target adherence 
to treatment regimens. Given the increased usage of these technology tools in treatment 
management in adolescents with chronic illnesses, they suggested need for research to evaluate 
cost-effectiveness, sustainability, and benefits of smartphone-based tools.   
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In another prospective study, Wu et al. (2018) studied adolescents and young adults with 
cancer. They used a medication reminder smartphone application and examined the feasibility 
and acceptability. Each participant received four weeks of training about the usage of the 
smartphone application for medication reminders and was required to use this application for 
eight weeks as an adherence intervention. Also, each participant completed a weekly online self-
report questionnaire that included questions about the usage of the application, and they received 
reminder prompts to take medication.  The authors concluded that the smartphone application 
was easy to use and useful to promote medication adherence.   
 Recognizing adherence barriers to maximize impact of MIP.  In a review, Prendergast 
and Gaston (2010) compared risk factors associated with non-adherence to immunosuppressants 
in young adult and older kidney transplant patients. They described a lack of education regarding 
treatment, health care coverage, social support, and complex treatment regimen as adherence 
barriers in young adults. They suggested that an adherence intervention must be 
multidimensional to have successful implication. They reported that non-adherence to 
immunosuppressive therapy is a major risk factor in post-renal transplant recipients that results 
in graft failure. Therefore, to ensure optimal clinical outcomes, emphasis must be geared towards 
ongoing education, focusing on the importance of adherence to immunosuppressive agents. In a 
meta-analysis, Shellmer et al. (2011) reviewed factors related to implications of nonadherence in 
organ transplant pediatric recipients. They reported that suboptimal family and child functioning 
as a potential risk factor for non-adherence to the treatment regimen. They recommended family-
centered interventions that focus on improving family functioning and motivating adolescents to 
take ownership of the management of their treatment. They described that many studies found 
interventions to be effective when they are tailored to adherence barriers.   
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Kondryn et al. (2011) conducted a review of studies in teens and young adults ages 13-24 
years with oncological diseases. They concluded that a knowledge gap exists in interventional 
studies focusing on medication adherence in AYAs with cancer. They described multifactorial 
strategies to foster optimal adherence, such as addressing problems with patients, family 
functioning, treatment regimen, and health professional support.  McGrady et al. (2014) 
examined adherence patterns in adolescents ages 12-18 years with hematopoietic stem cell 
transplant and reported a rate of non-adherence of 27 to 63% among the transplant recipients. 
Given the inconsistency to treatment adherence across study participants, they recommended 
adherence promoting interventions involving the caregiver. They also suggested that adherence 
interventions can be implemented before discharge and after discharge based on patient needs. 
McCormick et al. (2016) studied association among emotional functioning, adherence barriers 
and treatment adherence in adolescents with solid organ transplants. They found that adolescents 
internalizing behaviors, such as depression and anxiety, and barriers to medication are 
interrelated and contribute to increasing non-adherence.  
In a review of literature, Morrison et al. (2017) reported non-adherence in adolescents 
and young adults with oncological illnesses consistently remained below 80-95%. They 
suggested using multiple measures for monitoring adherence such as therapeutic drug levels, 
self-report, and adherence barriers of patient and caregiver. They concluded that researchers 
should utilize theoretical frameworks and models to guide adherence research that would aid in 
identifying variables, interventions, and outcomes. Pai et al. (2017) examined rates of non-
adherence to prescribed oral medication in post-HSCT children for six months after discharge. 
They recruited fifty post-HSCT children ages 0 – 16 years with their caregiver. They measured 
adherence using an electronic pill bottle and found that average adherence percent decreased 
over six months from 63% at one-month post discharge to 57% at six months post discharge. 
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They found a decline in treatment adherence with the increased rates of infection across the six 
month post-transplant duration.  
In a multicenter study, Danziger-Isakov et al. (2016) examined perceived adherence 
barriers in children and adolescents of solid organ recipients and their guardians.  They found 
that caregivers of adolescents stated increased perceived adherence barriers versus caregivers of 
younger patients. They stated that patients reported more medication ingestion barriers and side 
effects than their caregivers. They recommended perceived barriers to medication adherence can 
be easily assessed in an outpatient setting and providers can focus their interventions accordingly 
to promote adherence. Foster and Pai (2014) reviewed studies conducted in kidney transplant 
adolescents and young adults. They reported three main elements that impact adherence, namely 
patient-related, social and economic, and therapy-related. There were two reported methods for 
measuring adherence, direct and indirect. The direct method is witnessing ingestion of 
medication and monitoring serum drug levels while the indirect method involves electronic 
monitoring, pill counts, pharmacy records, self-report, and caregiver and/or parent reports. They 
recommended program-level adherence intervention approaches in kidney transplant recipients if 
administered at a regular interval.  By providing ongoing guidance and monitoring change, 
sustainable treatment compliance for long term graft survival may be accomplished through 
quality care.  
Theory  
The social cognitive theory (SCT) is influential for behavior modification and has been 
widely used in clinical practice. The SCT provides a framework for understanding human 
thought and behavior. The core determinants of SCT include personal, behavioral, and 
environmental factors that are interrelated to each other (Patton et al., 2017). The concept of 
social cognitive theory includes eight steps that provided an outline for the project (see Appendix 
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D).  Observational learning is the first step where participants and their caregivers acquired 
knowledge through the MIP approach. They observed and learned skills during interactive 
education sessions. The next step is self-efficacy which is a key construct of this model. Self-
efficacy is an important quality that participants and caregivers possess and that facilitated them 
to attain their goal of adherence to the medication regimen. Participants and caregivers were able 
to adopt behavior modification and organizational skills that enabled them to self-manage their 
treatment schedule (Patton et al., 2017). The internal and external environment ties participants 
and caregivers into a reciprocal relationship with the environment and behavior, resulting in 
behavior modification through learned skills (Patton et al., 2017). The final and most crucial step 
is long–term change that enabled participants and caregivers to sustain learned skills and carry 
out their tasks effectively (Patton et al., 2017). The goal of this project was to establish 
sustainability among participants through behavior modification that assisted them in achieving 
adherence to treatment management for a longer duration.  
Methods  
IRB Approval, Ethical Considerations, and Funding  
The Institutional Review Board at a tertiary care pediatric hospital reviewed and 
approved the project as an evidence-based quality improvement (EBQI) project (see Appendix 
E).  The privacy and confidentiality of the participants and the data were maintained. Before 
enrolling the participants, the author explained how the information would be used so that the 
process would facilitate their decision making. No ethical concerns or issues were raised by 
enrolled participants.  The estimated cost for the project was approximately $500 (see Appendix 
F) and included handouts for education sessions for project team members and participants, as 
well as pillboxes for participants.  
Setting and Participants 
MEDICATION ADHERENCE   15 
 
 
 
The evidence-based practice project was implemented at a tertiary care pediatric hospital 
in the Midwest. The project design was quasi-experimental with a prospective cohort. Two 
AYAs with hematopoietic stem cell transplant with their caregivers were enrolled after their 
discharge from the inpatient bone marrow transplant (BMT) unit of a tertiary care pediatric 
hospital.  Participants who were clinically unstable, cognitively impaired, and younger than 11 
years and older than 20 years were excluded from the intervention.  
Evidence-based Intervention 
The intervention applied was a multicomponent intervention package (MIP) and 
MedActionPlan PRO app with checklist. A month before the launch of the project, the project 
team, including the bone marrow transplant outpatient nurse practitioners (NPs) and pharmacists, 
attended two 180 minute training sessions led by the project clinical expert to ensure 
standardized implementation of the MIP. The HSCT recipient ranged from 12 – 20 years who 
were ready to be discharged from the inpatient unit along with their caregivers were approached 
by a project team member. During pre-intervention, the participants were required to complete 
the Adolescent Medication Barrier Scale (AMBS) and Parent Medication Barrier Scale (PMBS) 
at the initial outpatient visit. The content of each outpatient visit was based on standard BMT 
protocol including history and physical exam and routine lab draw. At each visit, the BMT 
pharmacists reviewed the medication list and asked if refills were needed for mediations.  
Following the initial visit, each enrolled participant was scheduled for four weekly MIP sessions, 
and these were incorporated into their regular outpatient visits to prevent multiple trips to the 
clinic after discharge. These follow up visits were comprehensive, lasting about 60 to 90 
minutes. Consistent with the evidence on MIP, these weekly sessions included an educational 
and organizational intervention (week 1), behavior modification (week 2), guided problem-
solving training (week 3), and family functioning (week 4). The participants also received 
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information and training based on their choice of MedActionPlan PRO app or checklist. Also, 
enrolled youth completed a weekly (week 1 through week 4) self-reported adherence behavior 
questionnaire. 
At the 4-week session, the intervention was individualized based on the pre-intervention 
assessment using AMBS and PMBS findings.  Upon completion of the MIP, at week 5, 
participants completed the post-treatment AMBS, PMBS, and adherence intervention satisfaction 
survey for youth and parents. Pre and post-intervention data from the AMBS, PMBS, and 
MedActionPlan PRO app or checklist smartphone application usage were compared to determine 
the impact of the intervention package on medication adherence (see Appendix G). 
Change Process and Evidence-Based Model  
The Change Curve Model was used in this project. This model supports basic 
assumptions for change and is useful in recognizing the stages of individual transition and 
organizational change (Melnyk & Fineout-Overholt, 2015). This five–stage process focuses on 
stagnation, preparation, implementation, determination, and fruition within the model (Melnyk & 
Fineout-Overholt, 2015). While developing this project, the author addressed stagnation and 
preparation stages of this change process (see Appendix H).   
The Stetler Model of Evidence-Based Practice was used to guide the evidence 
implementation in this project. The model is comprised of five phases including preparation, 
validation, comparative evaluation/decision making, translation/application, and evaluation 
(Melnyk & Finout-Overholt, 2015).  The author utilized this model in the development of the 
project by identifying a problem, locating and synthesizing evidence regarding the prevalence of 
non-adherence in AYAs with hematopoietic transplant recipients, and designing a practice 
change that was implemented through the project.  
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There is a high possibility of project sustainability after completion. The author plans to 
promote use of these intervention as standard of care for post-BMT outpatient follow up visits. 
The delivery of MIP with the app and checklist are effective interventions for promoting 
medication adherence. The AMBS and PMBS can continue to be utilized to assess adherence 
barriers, and education can be tailored accordingly. The use of the MedActionPlan PRO app with 
checklist can be encouraged to facilitate daily management of the treatment schedule. The 
utilization of these interventions can increase knowledge regarding adherence and self-
management of the treatment regimen that ultimately improves adherence in this specific 
population.  
Study Design  
The project was a pilot, quality improvement initiative with a quasi-experimental, one 
cohort design.  The impact of the MIP and MedActionPlan PRO app with checklist was 
measured by the change in adherence and self –management of the treatment schedule, designed 
to improve treatment efficacy. Medication adherence barriers were assessed using AMBS and 
PMBS pre and post-treatment sessions.  
Validity  
 Given that the project was a pilot study with a small sample, there are potential threats to 
the internal and external validity or transferability of the quality improvement initiative to other 
similar sites.  Also, the self-selection through convenience sampling is a threat to internal 
validity. Moreover, participant attrition or lack of adherence to the protocol may pose a threat to 
the internal validity and quality care if a participant chooses not to complete the MIP 
intervention or demonstrates inconsistency in using the MedActionPlan PRO app with checklist. 
However, the internal validity of the project is strengthened by using valid and reliable tools, 
namely PMBS and AMBS. The external validity of this proposed project is enhanced by the 
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diverse demographics of HSCT recipients at a tertiary care pediatric hospital. The internal and 
external validity was improved by using inclusion criteria during recruitment and an evidence-
based intervention   
Outcomes and Measurements Instruments 
The outcome measures included optimizing adherence to medical treatment and self-
management of the treatment schedule. The AMBS and PMBS assessment questionnaires 
evaluate perceived barriers to medication adherence. The PMBS consists of 16-items with a max 
score of 80 and has a Cronbach α of 0.87 which indicates strong internal consistency. The 
AMBS consists of 17-items with a max score of 85 and a Cronbach α of 0.86 which indicates 
strong internal consistency. The feasibility and acceptability of the MIP were assessed via 
participant attendance, attrition, and completion of the assigned task. The self-reported use of the  
MedActionPlan PRO app with checklist was assessed by usage and self-management of the 
treatment schedule. A self-reported adherence behavior questionnaire consisted of a 3-item 
measure to assess change in adherence behavior from baseline to post-intervention. The 
questionnaire addressed the percentage of medication taken, missed doses, and reason for missed 
doses of immunosuppressants, antiviral, and antifungal medications. Each enrolled youth 
completed the adherence behavior questionnaire from pre to post-intervention. The satisfaction 
survey for youth and parents consisted of a 12-item measure to assess enrolled youth and 
caregiver satisfaction with treatment sessions, including the content of educational sessions, 
perceived impact on adherence, and the likelihood of following through treatment 
recommendations. Responses were provided on a 4-point Likert scale (0 = Not at all, 1 = 
Somewhat, 2 = Very, and 3 = Extremely). This survey was administered to each patient and 
caregiver upon completion of interventions (see Appendix J) 
Quality of Data  
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The measures chosen for this project were frequently used in studies focused on 
medication adherence in transplant and chronic health conditions. The PMBS and AMBS have 
been widely used in research, as well as in the clinical settings, to identify perceived barriers to 
medication. The interventions in MIP have been utilized in the research in optimizing adherence 
by tailoring and providing education to develop problem-solving and organizational skills 
through behavior modification. Technology-based interventions have been increasingly used 
over time to monitor adherence in individuals with chronic illness.  A standard self-reported 
adherence behavior questionnaire was used to assess change in adherence. This evidence-based 
pratie was an initial approach in utilizing multicomponent intervention package for adolescents 
and young adults with post-HSCT who are potentially at risk of less than optimal self-
management of a complex treatment regimen post-discharge. However, there is evidence for 
improved compliance with the administration of adherence intervention among youth and young 
adults with chronic illness. One study that evaluated the efficacy of MIP among youth with 
inflammatory bowel disease found substantial improvements in the study population including 
knowledge about their disease and treatment, self-reported adherence, and clinical outcomes 
(Maddux et al., 2017).  
Analysis Plan 
The AMBS and PMBS scores were evaluated to determine the decrease in the medication 
adherence barrier from baseline to post-intervention. Self-report adherence behavior responses 
were collected from baseline to post-intervention to evaluate the change in adherence from 
baseline to post-intervention. Similarly, the self-reported MedActionPlan PRO checklist was 
used to estimate the self-management of the treatment schedule. The intent of this evidence-
based project was the delivery of MIP and use of MedActionPlan PRO app with checklist to 
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favorably impact medication adherence and self-management of treatment regimen in post-
HSCT adolescents and young adults. 
Results  
Two participants, ages 12 – 20, were enrolled in the project, including one female with 
her mother (caregiver) and one male with his mother (caregiver).  Both enrolled participants 
were Caucasian, diagnosed with Acute Lymphoblastic Leukemia, received HSCT for a 
malignant disease, and were on multiple prescribed oral medicine at the time of discharge.  
The interventions used for this project included a multicomponent adherence promoting 
intervention package with a MedActionPlan PRO app with checklist, The MIP is comprised of 
four sessions including an educational and organizational intervention (session 1), behavioral 
modification (session 2), problem-solving skills and monitoring adherence (session 3) and family 
functioning. Each session occurred one week apart, lasted approximately 30 to 40 minutes, and 
took place at the patient BMT follow up outpatient visit. Both, enrolled participants choose to 
use the MedActionPlan PRO checklist instead of the MedActionPlan PRO app on their 
smartphone. The MedActionPlan PRO checklist was reviewed with each enrolled participant at 
each weekly visit, with a total time spent at each visit between 15 -2 0 minutes. The 
MedActionPlan PRO checklist review included time and dose of medication taken, missed 
medication dosing, and reasons for not taking medication at the prescribed time. At the session, 
each enrolled participant was provided with an updated current MedActionPlan PRO checklist 
for the coming week which was discussed with the enrolled participants until they voiced proper 
understanding of their current prescribed oral medication before their discharge from the clinic. 
Both of the enrolled youth attended all the sessions as scheduled and no participant withdrew 
from the project. 
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Each enrolled youth along with their caregiver completed the Adolescent Medication 
Barrier Scale (AMBS) and the Parent Medication Barrier Scale (PMBS) pre-intervention and 
post-intervention after receiving the four session MIP. The AMBS includes 3 subscales namely 
Disease Frustration/Adolescent Issue (AMBS -D), Regimen Adaptation/Cognitive (AMBS – R) 
and Ingestion Issues (AMBS – I). The PMBS includes four subscales, namely Disease 
Frustration/Adolescent Issue (PMS -D), Regimen Adaptation/Cognitive (PMBS- R), Ingestion 
Issue (PMBS -I), and Parent Reminder (PMBS-P). For both AMBS and PMBS, higher scores 
indicate a greater medication adherence barrier. Participant 1 indicated a decrease in AMBS-D, 
AMBS – R and AMBS -I scores from pre to post-intervention. Also, from pre to post 
intervention, participant 1 developed symptoms of skin graft versus host disease (GvHD) and 
another immunosuppressant medicine was added. This participant reported increased symptoms 
including pain, headache, nausea, vomiting, fatigue and weight gain.  This youth’s development 
of skin GvHD, ongoing systemic symptoms, and persistent minimal residual disease (MRD) 
post-transplant by molecular genetics resulted in increased disease frustration in the parent which 
were reported during clinic visits. This is believed to account for the parent’s report of increased 
disease frustration on the PMBS from pre to post-intervention. Participant 1 showed an increased 
PMBS -D score, a decreased PMBS- R score, no change in PMBS-I score, and decreased PMBS 
– P score at post interventions.  
Participant 2 showed an increased AMBS – D score, no change in AMBS – R score, and 
an increased AMBS – I score from pre to post intervention. Throughout the project, this youth 
experienced a reoccurrence of skin GvHD rash covering more than 50% of the body surface area 
despite being on two immunosuppressant agents. At this time, in the clinic, the youth received 
additional intravenous therapy weekly for his GvHD. Participant 2 completed the PMBS pre-
treatment session, but the post-treatment PMBS was not completed. The caregiver of participant 
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2 did not attend any weekly intervention on medication adherence given that participant 2 is a 
young adult and capable of taking responsibility for his care. This youth attended all treatment 
sessions without the parent.  
An adherence behavior questionnaire evaluated self-reported adherence, pertaining to the 
immunosuppressant, antiviral, and antifungal therapy. Each enrolled youth completed this 
questionnaire weekly for four weeks. Both participants reported 76 to 100% adherence to 
prescribed immunosuppressant, antiviral, and antifungal medications at both pre and post-
intervention.   
The other notable effort demonstrated from both of the youth was checking each 
medication on the MedActionPlan PRO checklist after ingestion. They brought the checklist with 
them at each visit and verbalized that the MedActionPlan PRO checklist assisted in tracking their 
medication time, frequency, and doses. 
The MIP intervention feasibility was demonstrated by 100% attendance for all enrolled 
participants. Due to readmission, sessions were rescheduled for one participant within 2-3 days 
of the originally scheduled sessions.  Youth and caregivers were provided a satisfaction survey at 
the post-treatment session. However, participant 1 did not complete the satisfaction Youth 
Survey but the mother completed the Parent Survey. She reported that the treatment sessions 
were “not at all helpful”; however, she acknowledged that the MedActionPlan PRO checklist 
was “somewhat helpful” and her likelihood of following through on treatment recommendations 
as “somewhat helpful.”  When asked what this parent liked least about the intervention study, 
she answered that checking medication on the MedActionPlan PRO checklist was “more work” 
and was “somewhat helpful.”  Participant 2 completed the satisfaction Youth Survey and 
endorsed that each treatment session was “somewhat helpful,” including the educational and 
organizational intervention, behavior modification, problem-solving, and adherence monitoring.  
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Participant 2 rated adherence since receiving the adherence intervention as “somewhat 
improved,” stress or worry about his adherence as “somewhat reduced,” and endorsed being 
“somewhat likely” to follow through on treatment recommendations. Furthermore, the 
participant rated that the project improved his organization.  
Discussion 
Based on the interventions delivered during the duration of the project, one of the 
primary findings pertains to youth participation in treatment sessions. Participants were engaged 
in discussions regarding their self-care and medication adherence and showed 100% attendance 
throughout the weekly educational sessions, indicating participant willingness to attend sessions 
and gain greater ownership for their care.  
The project was implemented in a hematology, oncology, bone marrow transplant 
outpatient clinic setting at a tertiary care pediatric hospital. The outpatient clinic was an 
appropriate setting for the implementation of the project because the participants and their 
caregivers were familiar with the clinic culture and the staff. Each room in the clinic was quiet, 
spacious, and well lighted. The participants were scheduled for weekly sessions the same day of 
their BMT routine follow up, and no additional visits were necessary or expected from patients. 
Also,  the BMT clinic staff were informed about the allocated rooms to conduct project sessions 
to avoid intermittent interruption during treatment sessions. The allocated rooms were prepared 
for sessions prior to the arrival of the participant. Each trained advanced practice nurse was 
provided with a folder containing treatment session handouts and questionnaires for each visit. 
The clinic manager and other clinic staff were also aware of the project including interventions 
to be conducted and duration of the visits. 
The BMT outpatient advanced practice nurses and BMT pharmacist received training by 
a licensed psychologist at the project site for delivery of the MIP, while the BMT pharmacist 
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provided training for use of the MedActionPlan PRO application. The facilitated interactive 
intervention sessions with each youth and their caregiver included timely completion of weekly 
educational sessions, review of the medication checklist such as missed medicine doses, reasons 
for missed dose, and discussion of the updated medication checklist including missed medication 
doses and the revised medication checklist with changes in medication time, doses, and 
frequency. Clinic staff were kept informed of the project which aided in assigning clinic rooms 
and efficient clinic flow. A folder placed in the room before participant arrival assisted in the 
completion of the weekly self-report by the youth and questionnaire in a timely fashion. The 
project team received support from the BMT clinic staff that facilitated successful 
implementation.   
The project examined the feasibility and impact of utilizing a MIP to increase medication 
adherence in AYAs with bone marrow transplant recipients. The enrolled participants 
demonstrated 100% attendance for weekly intervention sessions. This result supports previous 
studies showing a high level of attendance to adherence-focused MIP in youth with diabetes type 
1 (Hood et al., 2010) and youth with inflammatory bowel disease (Maddux et al., 2017). Each 
enrolled participant and their caregiver opted for MedActionPlan PRO checklist for monitoring 
adherence instead of the application. Participants were required to check each medication on the 
checklist after ingestion. Both participants reported taking their oral prescribed medicine on time 
and reported no missed medication doses. They also completed the weekly MedActionPlan PRO 
checklist by placing checkmarks in the medication column.  
Additionally, each youth completed a weekly self-report of adherence and stated 76% to 
100% adherence.  The use of self-reported measure of adherence is common practice in 
pediatrics (Pai & McGardy, 2015). Medication adherence barriers were evaluated for each 
enrolled youth and their caregiver, pre and post-intervention using the AMBS and the PMBS. In 
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the project, comparing scores on the AMBS and the PMBS from pre-intervention to post-
interventions seems to reflect changes in medication adherence barriers with alteration in health 
status in AYAs with chronic conditions. The changes in health status resulted in changes in 
medication, which potentially impacted reports of medication adherence barriers.  
Limitations 
This project has many limitations. Both the enrolled youth endorsed 100% medication 
adherence via self-reported questionnaire and MedActionPlan PRO checklist from week 1 to 
week 4; therefore, no changes in the adherence were observed. A second limitation is a reliance 
on self -report of adherence via questionnaire and manual checking of each medication on the 
MedActionPlan PRO checklist which can overestimate adherence by the enrolled patients. The 
use of an objective measure of adherence, such as the smartphone app of MedActionPlan PRO or 
lab values for the drug level, would provide more accurate estimates of medication adherence. 
Another limitation is the actual measure of adherence which was developed for this project. The 
use of a validated tool is likely to detect more subtle variation in medication adherence among 
patients. The other notable limitation was the small sample size. This sample was primarily AYA 
bone marrow transplant recipients from a single institution within a given timeline which limits 
conclusions drawn regarding the impact of the intervention on medication adherence, 
generalizability to other patients, and transferability of the evidence-based intervention to other 
settings. .  
  During the project period, it was noticed that patients consistently checked their daily 
prescribed medicine on MedActionPlan PRO checklist that was provided to them on a weekly 
basis. This assisted them in knowing the name, dose, and frequency of the medications. The 
author is concerned about the possibility of losing or weakening of this gained attribute over 
time. The BMT advanced practice nurses and BMT pharmacist will continue to provide 
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medication checklists to patients at every outpatient BMT follow up visit and ensure use by 
checking with the patients at their clinic visit. 
Throughout the project, efforts were made to minimize limitations by ensuring 
consistency in the delivery of intervention sessions such as highlighting the goals of each 
educational session, making it interactive, and finishing the session on time to maximize 
attendance. The BMT pharmacist reviewed each medication checklist with the patients and their 
caregivers at each visit to minimize errors in completing the checklist. Appointments for next 
visits were scheduled based on participant convenience. Data collection forms were reviewed 
with participants to lessen the possibility of error in completing the forms.  Given the small 
sample size and reports of 76%- 100% adherence at baseline, a conclusion regarding the impact 
of the intervention on medication adherence and positive change in medication adherence in the 
project participant is not valid.   
Interpretation 
The outcome expected was that delivery of the intervention on medication adherence, 
combined with the smartphone medication reminder application, would improve treatment 
adherence in AYAs who are HSCT recipients. While the delivery of the intervention on 
medication adherence was achieved as expected, the impact of the MIP intervention was not 
demonstrated because of the small sample size. Additionally, project participants choose to use 
the MedActionPlan PRO checklist instead of the MedActionPlan PRO app on the smartphone to 
measure adherence. Due to this variation of intervention, project outcomes were affected. Given 
the complexity of treatments for HSCT recipients, as well as frequent changes in medication 
regimens in this patient population, relying on accurate patient self-reports of medication 
adherence cannot be expected and objective adherence measures should be used to validate 
improvement in adherence.  
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In the project, the project team expected the enrolled participants, including patients and 
their caregivers, to complete the study questionnaires, medication barrier scales, and satisfaction 
surveys, but this did not occur as expected. The caregiver of youth 2 completed the PMBS pre -
treatment but did not complete the post-treatment PMBS. Similarly, participant 1 did not 
complete the youth satisfaction survey post- treatment session.  
In conclusion, the implementation of this project provided an experience for both of the 
enrolled youth in knowing their medication name, dose and frequency. They came to the clinic 
with a list of medications to be refilled and they also voiced if a medication helped relieve their 
symptoms. Both patients were present for four weekly educational sessions and endorsed 100% 
medication adherence via self-report. Based on the targeted patient population in the project, the 
bone marrow outpatient clinic was an appropriate setting for the implementation of this project 
The team suggests the use of a validated tool to detect more subtle variation in 
medication adherence among patients, such as technology-based tool which can potentially 
improve the accuracy of self-report. Because of the frequent changes to the treatment regimen 
and the potential for many side effects of the treatments, the intervention may need to expand in 
focus on education regarding adherence to include a more thorough description of side effects as 
well as anticipatory guidance regarding solutions to address side effects.  
Because of the negative ramification of medication adherence, understanding and 
addressing adherence is imperative. Evidence-based interventions on medication adherence 
combined with technology-based intervention have been shown to result in improved adherence 
in AYAs with chronic illness.  The impact of these interventions is substantial as non-adherence 
to medication in this population leads to frequent hospitalizations due to complications, 
increasing healthcare expenditure. We suggest there is a greater need for this study to be 
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replicated in a larger sample of patients following bone marrow transplant to fully evaluate the 
impact and effect of the interventions on medication adherence 
   The actual cost of the study was $500.00 and included handouts, questionnaires, and 
surveys for participants. The author calculated the cost of pillboxes; however, these were 
donated for participants by the hematology, oncology division at the project setting. The actual 
cost of the intervention for each enrolled youth was $ 10.00 – $15.00. The cost of the 
interventions was nominal and the likelihood of sustaining the intervention is possible because 
there is no potential economic burden to implement interventions.  
Conclusion 
Medication adherence is a multifaceted human behavior. Across the studies, medication 
non-adherence has been reported as a key public health issue resulting in suboptimal clinical 
outcomes and increased healthcare costs. Several factors contribute to medication non-adherence 
such as individuals, social, environmental, knowledge deficit of disease, inadequate self-efficacy, 
and beliefs about medications. Evidence shows that when adherence interventions are tailored 
specifically to perceived adherence barriers, AYA normative developmental behaviors, and 
psychosocial factors such as family functioning, then improvements in medication adherence are 
most significant. Major evidence exists in research that these interventions are feasible, 
applicable, and promising in promoting adherence in AYAs with chronic health conditions 
including transplant. With the negative consequences of poor adherence following HSCT and 
implications of patient outcomes, the application of adherence focused-intervention is promising 
in improving quality care.  
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Appendix A: Definition of Terms 
1. Adherence: The World Health Organization defines adherence as: “the extent to which a 
person’s behavior – taking medication, following a diet, and/or executing lifestyle changes, 
corresponds with agreed recommendations from a health care provider” (Sabaté, 2003, pp.3) 
2. Adherence focused-interventions: intervention that are emphasize adherence 
3. Adolescent/ Young adult: based on ages: a) Early adolescence: approximate ages 10 to 13, or 
middle school years; b) Middle adolescence: approximate ages 14 to 17, or high school years; 
and c) Late adolescence/ Young adult: approximate ages 17 to 25, or college or 4 years of work 
after high school. 
4. Chronic illness: a health condition that lasts more the 3 months  
5. Hematopoietic stem cell transplant: a procedure in which donor stem cell are infused 
intravenously in recipient  
6. Technology-based interventions: A type pf electronic sent and received via mobile phone 
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Appendix B: Hierarchy of Evidence Table 
Rating System for the Hierarchy of Evidence 
For an Interventional Inquiry 
(Modification by Dr. Lindholm for course N5613) 
Level  I  
Evidence from a systematic review or meta‐analysis of all relevant 
RCTs.  Evidence‐based clinical practice guidelines based on 
systematic reviews of RCTs).*                                                                       
Level  II  
Evidence obtained from well‐designed RCT.                                             
Quantitative systematic review of well‐designed controlled trial 
without randomization. 
Level  III  
Evidence obtained from well‐designed controlled trial without 
randomization (quasi‐experimental).                                                          
Quantitative systematic review of case‐control, cohort, or 
correlational studies.                                                           
Level  IV 
Evidence from well‐designed case‐control or cohort study (or 
cross‐sectional study)  
Level  V  
Evidence from systematic review of quantitative descriptive (no 
relationships to examine) or qualitative studies. 
Level  VI  
Evidence from a single quantitative descriptive (no relationships to 
examine in the study) or qualitative study  
Level  VII  
Evidence from the opinion of authorities and/or reports of expert 
committees 
Melnyk, B & Fineout‐Overholt, E (2015). Evidence‐based practice in nursing and healthcare: A guide to best practice 
(3rd ed.).  Philadelphia: Wolters Kluwer. The levels of evidence adapted by Lindholm, L (2017) from Melnyk & 
Fineout‐Overholt, Rating System for the Hierarchy of Evidence for Intervention/Treatment Questions (p.11). 
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Appendix C, Synthesis of Evidence   
Inquiry: Among the adolescents and young adults who are recipients of hematopoietic stem cell transplant (HSCT), does 
implementation of a multicomponent intervention package (MIP) and smartphone medication reminder application improve adherence 
and self-management of treatment regimen, during a three-month period at a bone marrow transplant outpatient clinic? 
Article Purpose of 
Study or 
Review 
 Research 
Design 
 Evidence evel 
 Variables 
 Sample 
 Population
 Setting 
Measurement 
of Variables 
 Results 
 Data Analysis 
 Findings 
Relevant to 
Project 
 Limitations 
Subtopic: Multicomponent intervention package (MIP) to promote adherence 
Pai et al. (2014)  
Systematic review 
and Meta-analysis 
of psychological 
Interventions to 
promote treatment 
adherence in 
children, 
adolescents and 
young adults with 
chronic illness 
 
Examine the 
effectiveness of 
adherence-
promoting 
interventions for 
youth with 
chronic health 
conditions 
 Systematic 
review with meta-
analysis of RTC 
 Level 2 
 Adherence & 
health outcomes 
 23 studies 
 Children, 
adolescents 
and young 
adults with 
chronic 
illness 
 
Bioassays, self-
report, 
questionnaires, 
parent-report 
questionnaires, 
semi-structure 
interviews, 
prescription refill
history, daily 
diaries & 
electronic 
monitoring 
device 
 In-person and 
technology-based 
interventions 
were significant 
(p level < 0.02) 
 Cohen’s d 
statistics & I2  
 Quality of the 
evidence base 
were evaluated 
using GRADE 
approach 
 High or unclear 
risk of bias was 
due to difficulties 
in blinding 
participants 
involved in 
psychological 
interventions.  
 Small number 
of studies coupled 
w/ diversity of 
pediatric 
populations and 
adherence targets 
Pai et al. (2015) 
Assessing 
medication 
adherence as a 
standard of care in 
pediatric 
oncology  
 
Examining 
medication 
adherence 
among pediatric 
cancer patients 
and develop 
evidence-based 
guidelines for 
supporting med 
 Review 
included 
prospective, 
cross-sectional, 
qualitative; RTC 
& guideline 
developed by 
experts  
 Level 7 
 14 studies  
 Children 
and 
adolescent  
oncology 
patients 
 GRADE 
criteria used to 
assess quality of 
evidence 
 Review 
concluded that 
there is moderate 
–quality evidence 
to support med 
adherence  
 Quality of the 
evidence base 
were evaluated 
 Integration of 
routine adherence 
monitoring into 
standard of care 
in pediatric 
oncology could 
optimize 
treatment 
adherence and 
health outcomes 
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adherence in 
clinical care  
 Quality of 
evidence
using GRADE 
approach  
Hood at el. (2010)  
Interventions with 
adherence-
promoting 
components in 
pediatric type I 
diabetes 
 
Review 
interventions 
with adherence-
promoting 
components and 
their impact on 
glycemic control 
via meta-analysis
 Meta-analysis 
of RTC 
 Level 2 
 Adherence 
promoting 
intervention and 
glycemic control 
 15 studies 
 Youth < 19 
years with type 
I diabetes 
 
Mean effect 
size for pre- to 
post-treatment 
change for the 
intervention 
verses control 
group  
 Analysis for 
pre to post-
treatment effects 
for the 
intervention 
group was 
significant (P < 
0.05) versus 
control group 
achieved P 0.01 
– 0.23)   
 Weighted least 
square for effect 
size 
 Q statistic used 
to analyze 
studies included 
in meta-analysis 
 Glycemic 
control will not 
improve if 
interventions 
focus on direct, 
behavioral 
process while 
neglecting 
emotional, social 
& family 
processes.  
 Few of studies 
targeted “high 
risk” youth who 
consistently 
demonstrate high 
A1C values and 
had fewer 
resources
Maddux et al. 
(2017) 
A pilot study 
evaluating the 
impact of an 
adherence-
promoting 
intervention 
among non-
adherent youth 
with inflammatory 
Examine 
feasibility and 
impact of a 
multicomponent 
adherence 
intervention 
among youth 
with 
inflammatory 
bowel disease 
(IBD) 
 Longitudinal, 
single-site, 
multiple base-
line design 
(MBD) cohort 
study  
 Level 4 
 Increased in 
adherence from 
baseline to post-
intervention 
 12 IBD 
patients 
 
 session 
attendance & 
completion of 
assigned 
behavioral tasks
 Electronic pill 
boxes to 
measure 
adherence  
 Adherence to 
medication 
included 
baseline, post-
 Mean 
adherence 
increase 12% 
from baseline to 
post-intervention 
(p < 0.01) and 
6% from 
baseline to 1 
month post 
follow up (p < 
0.025)  
 IBM’s SPSS 
version 22 
 Delivery of a 
multicomponent 
adherence 
interventions to 
poorly adherent 
youth with IBD 
can results in 
significant 
improvement in 
their adherence to 
oral medication 
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bowel disease 
(IBD) 
intervention 
and 1-month 
follow up 
statistics. Chi-
square and 
General Linear 
Model were used
Subtopic: Utilization of technology-based intervention in enhancing treatment adherence. 
Sheller et al.(2016)  
Development and 
field testing of 
Teen Pocket PATH 
(TPP), a mobile 
health application 
to improve 
medication 
adherence in 
adolescent solid 
organ recipients 
 
Developed and 
tested the 
prototype of TPP 
– an mHealth 
application to 
promote 
medication 
adherence and 
enhance 
communication 
about medication 
management 
between 
adolescents and 
primary 
caregivers  
 Prospective 
cohort study  
 Level 4 
 Face to face 
usability 
sessions, 6 
week field test 
of TPP and 
debriefing 
session at the 
end of field 
testing 
 7 adolescents 
11 – 18 yrs 
with solid 
organ 
transplant who 
were >/= 1 yr 
post-transplant 
(included 4 
liver-transplant, 
2 heart 
transplant and 
1 lung 
transplant) with
caregivers 
 Transplant 
unit 
Demographic 
questionnaires, 
level of 
electronic 
device/media 
use and TPP 
 100% 
participants 
expressed TPP 
effective for 
monitoring 
medications  
 PSSUQ- 
validated 
measure used in 
the development 
of technological 
application 
 TPP found to 
be a promising 
mHealth 
adherence tool 
 Lack of ethnic 
diversity in study 
sample and TPP 
was tested in a 
single center – 
limiting 
generalizability  
Badawy & Kuhns. 
(2016). Economic 
Evaluation of Text-
Messaging and 
Smartphone-Based 
Interventions to 
Improve 
Medication 
Adherence in 
Adolescents with 
Chronic Health 
Conditions (CHC): 
Conduct an 
economic 
evaluation of text-
messaging and 
smartphone-based 
interventions that 
focus on 
improving 
medication 
adherence in 
adolescents with 
CHCs. 
 Systematic 
Review of RTC 
 Level 2 
 Technology-
based 
intervention, 
adherence 
measures and 
rates, disease 
related 
outcomes and 
cost-
 156 studies 
 12 – 24 yrs 
children and 
adolescents 
with CHCs  
 Hem/Onc and 
adolescent 
medicine 
 GRADE 
criteria used to 
assess quality 
of evidence  
 
 
 
 
 
 
 
 
 Authors found 
no evidence to 
support the cost 
effectiveness of 
technology-
based text 
messaging and 
smartphone app 
interventions 
 Quality of the 
evidence base 
were evaluated 
 Technology-
based 
interventions to 
support 
medication 
adherence are 
promising, but 
need to be tested 
and validated 
 Not all articles 
met pre-defined 
criteria. 
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A Systematic 
Review 
 
 
 
 
 
 
effectiveness of 
technological 
intervention 
 
 
 
 
 
 
 
using GRADE 
approach.  
Smartphone app 
initiative have 
been piloted but 
data generated 
from these 
studies are 
limited. Efficacy, 
effectiveness and 
economic 
evaluation is 
warranted. 
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Story et al. 
(2016)  
Monitoring 
therapy 
adherence of 
Tuberculosis 
patients by 
using Video-
enabled 
electronic 
device 
Examine the 
effectiveness of 
video or virtually 
observed therapy 
(VOT) in 
improving 
tuberculosis (TB) 
patient outcomes  
 Review of 
controlled trials  
 Level 3 
 effectiveness 
of VOT 
 Patients with 
TB on 6 months 
or 2 years 
therapy  
N/A  VOT is new and 
emerging 
technology with 
limited 
knowledge about 
its effectiveness 
and limitations 
 
 VOT needs to be 
evaluated in more 
diverse conditions 
and settings 
 Synergies 
between digital 
health & 
traditional 
approaches to 
improve patient 
outcomes needs to 
be explored.   
Creary et al. 
(2014)  
A pilot study of 
electronic 
directly 
observed 
therapy to 
improve 
hydroxyurea 
adherence in 
pediatric 
patients with 
sickle cell 
disease 
 
Determine 
feasibility of 
electronic directly 
observed therapy 
(DOT) in 
improving 
hydroxyurea (HU) 
adherence  
 Prospective 
cohort study  
 Level 4 
 Feasibility and 
participants 
satisfaction with 
electronic DOT 
and HU 
adherence. 
Mean 
corpuscular 
volume (MCV), 
hemoglobin F % 
(HbF) 
 
 15 Sickle cell 
patients on HU 
therapy for >/= 6 
months  were 
enrolled but 14 
completed the 
study 
 Pediatric 
Hem/Onc 
 8 dimension 
of telehealth 
obtrusiveness, 
5-point Likert 
sacle survey to 
measure DOT’s 
intrusiveness, 
usability and 
functionality.  
 
 
 Participants 
medication 
possession ratio at 
study entry to the 
end of study 
improved from 
0.75 to 0.91 (p = 
0.02). HU 
adherence with 
DOT was 93.3%; 
MCV and HbF 
increased from 
96.0 to 107.2 (p = 
0.009) and 10.5 to 
11.4 (p = 0.03), 
respectively.  
 Study 
demonstrate 
electronic DOT is 
feasible, 
acceptable and can 
achieve high HU 
adherence  
 Single center 
pilot study. Need 
further study to 
confirm electronic 
DOT can improve 
HU adherence and 
impact clinical 
outcomes in 
children  
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 Morisky 
medication 
adherence scale 
(MMAS – 4), 
medication 
possession ratio 
(MPR) and video 
observationSubtopic:  Recognizing adherence barriers to maximize impact of MIP.   
Pai, et al. (2017). 
Poor adherence is 
associated with 
more infections 
after pediatric 
hematopoietic 
stem cell 
transplant 
Examine rates of 
outpatient oral 
medication 
adherence in 
children after 
hematopoietic 
stem cell 
transplant 
(HSCT) and 
incidence of 
infections 
 Controlled 
cohort study   
 Level 4 
 Relationship to 
medication 
adherence with 
incidence of 
infection 
 Control 
variable includes 
age, medication 
dosing schedule, 
medication taste, 
swallowing 
difficulty, time 
since transplant 
and transplant 
type 
 Predetermine 
medication 
selected by 
research team 
using a priori 
 
  50 post-HSCT
patients (aged 0-
16 years) and 
their primary 
caregivers  
  Bone 
marrow 
transplant 
outpatient 
clinic 
(hospital-
based) 
 Medication 
Event 
Monitoring 
System 
(MEMS) 
  Indicated no 
variables were 
significantly 
associated with 
GvHD within the 
model, including 
adherence (P > .05). 
 Older patient had 
significantly higher 
# of infections 
(P=.02) 
 lower adherence, 
associated with 
higher infections (P 
< .005) 
  Poisson 
Regression  
Analyses  
  Used 2 models 
1 with graft vs host 
disease (GvHD) and 
1 with infection 
outcome 
 Descriptive 
statistics were used 
to summarize 
  Study results 
lend substantial 
support for the 
generalizability 
of the findings to 
larger pediatric 
HSCT 
population 
  Potential for 
Hawthorne 
effect with 
electronic pill 
bottles.  
 Exact 
medication 
monitored for 
the sample 
varied because 
of heterogeneity 
of the diseases 
treated and types 
of transplant  
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demographic, illness
and treatment 
regimen 
characteristics. 
Morrison et al. 
(2017).  
Medications 
adherence 
hematopoietic 
stem cell 
transplant 
(HSCT): a 
review of the 
literature  
To report the 
state of the 
science about 
oral medication 
adherence during 
acute phase of 
HSCT across the 
lifespan.  
 Review of 
literature of 3 
descriptive and 
2 interventional 
studies   
 Level 5 
 Adherence to 
medication 
regimen  
 
 5 studies (2 
examine 
adherence in 
pediatrics, 2 in 
adults and 1 in 
both adults and 
pediatrics) and 
adults patient  
  Bone marrow
transplant unit 
 One study did 
not report 
measure of 
adherence but 
documented 
adherence 
percentile, one 
studies 
measured 
adherence using
pill count but 
majority of 
studies used 
self-report as 
measure of 
adherence 
 
  Adherence of 
medication decreased
overtime in majority 
of the studies. 
Suggested non-
adherence to 
immunosuppressant 
and oral antibiotic 
medication regimen 
could increase the 
risk of developing 
graft vs host disease 
 Used Morisky 
questionnaire for 
self-report showed 
adherence decreased 
over the 6 clinic 
visits by 1.53 (95% 
CI, 1.12 to 1.94 p = 
.0001) 
 
  Critical need 
for adherence 
research focused 
on measurement, 
intervention 
development and 
clinical 
integration in 
HSCT population
 All studies had 
small sample size
And lacked power 
for casual 
inference; all 
studies had 
attrition and/or 
missing data – 
contributed to 
small sample and 
limited analysis. 
Possible mono-
operation bias and 
mono-method 
bias due to using 
one method of 
adherence m 
McGrady et al. 
(2014).   
Adherence to 
outpatient oral 
medication 
regimens in
adolescent 
HSCT 
recipi ts 
 Examine 
adherence 
patterns in 
adolescents 
HSCT 
recipients 
 Controlled 
cohort study 
 Level 3 
 Individual 
adherence 
pattern, 
electronic pill 
bottles (medical 
Event Monitors 
– MEMS) that 
time-stamps 
each bottl  
opening, 
medications 
were not being 
dispensed from 
bottle 
 
 8 adolescents 
ages 12- 18 
years, 
recipients of a 
HSCT 
  Living with 
caregiver and 
fluent in 
English 
  Bone marrow
transplant 
outpatient clinic
(hospital-based)
 
 Electronic 
pill bottles 
(medical Event 
Monitors – 
MEMS) 
 
  Participants took 
73% of doses (SD =
13%), demonstrated
perfect adherence 
on 56% of days (SD
= 18%). Av rage 
monthly adherenc  
ranged f o  40 – 
91% and decreased 
over time. 
 Daily adher nce 
was calculated by 
dividi g the # of p ll
bottle opening/day 
by the # of 
prescribed doses for
that day. Weekly 
and monthly 
adherence values 
were calculated by 
computing the m an
of daily ad rence 
value across the 
specified time 
frame. The 
frequency and 
average length of 
medication 
interruptions (>/= 
24 hours between 
  Finding suggested 
adherence rates are 
similar to those in other 
pediatric populations 
and demonstrate the 
importance of routinely 
as ssing adherence in 
adolescents wh  have 
undergone HSCT 
  Cha ges i  
medication regimens 
may partially contribute 
to chang s in adherence 
over time.  
  Suggest patient-
centered, individualized 
adherence-promoti n 
efforts may be most 
effect ve.  
  Generalizability of 
this study is limited by 
its small sample size 
Prendergas & 
Gaston. (2010). 
Optimizing 
Medication 
Adherence: an 
Ongoing 
Opportu ity To 
Improve 
Outcomes After 
Kidney 
Transplantation 
 
 
 
Foster & Ahna. 
(2014). 
Adherence in 
Adolescent and 
Young Adult 
Kidney 
Transplant 
Recipients 
 
 
 Identification 
of risk factors 
nd measure 
that effectively 
address them 
im roving 
clinical
outcomes 
 
 
 
 
 
 
Review 
different ways 
in which 
adherence may 
be 
compromised 
and impact of 
poor adherence 
in adolescents   
 Mini-Review 
  Level IV 
 M dication 
monitoring, 
pati t self-
report, drug 
level 
 
 
 
 
 
 
 
Systematic 
Review 
  Level I 
 N/A 
 
 Patients of
renal allograft 
loss attributed to
chronic 
rejection in 
recipients with
functioning 
graft 6 months 
po t-transplant 
 
 
 
 
 
 Adolescent 
and Young 
Adult Kidney 
Transplant 
Recipients 
 
 Electronic 
medication 
monitoring, patient 
self- eport, drug 
level monitoring
 One study tested 
reliability of patient
reporting and 
physicia  
identification f 
non-adherence to 
electro ic 
monitoring 
 
 Dir ct m thods 
included: 
observation, drug 
level and biomarker
 Indirect methods 
included: electronic
monitoring, pill 
count, pharmacy 
records & self-
report 
 
  Use of repetitive
teaching to 
promote 
adherence. 
Combination of 
interventions via 
team approa h 
improves 
a herence  
 
 
 
 
 
 
 Effective 
interv ntion for 
adherence 
included: 
educ ion w/ 
combination of 
adherence 
monitoring,
promoti n of 
problem-solving, 
goal setting, 
development of 
routine and 
adherence support
  No study 
intervention was 
found t  be 
superior as 
interventions to 
improve dh rence 
needs to b  multi-
dimensional 
 
 
 
 Limitati  
i cludes: rug 
lev l do not 
provide 
information about 
adh rence 
patterns, 
Biomark r/tracers 
were xpensive 
and impr ctical; 
electronic pill box 
expensive and 
unattractive if 
part cipants u ng 
multi-dose pill 
box, self-report are
po r recall an  
overestimate 
adherence 
measurement. 
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Danziger-Isakov 
et al. (2016) 
Perceived 
barriers to 
medication 
adherence in 
pediatric and 
adolescent solid 
organ 
transplantation 
 
 
 
 
 
 
 Conduct 
comparison of 
perceived 
barriers to 
adherence in 
pediatrics and 
adolescent 
solid organ 
transplants 
 Cross-
sectional Cohort 
study 
  Level IV 
 Age, 
propensity 
score for age 
group, recipient 
and guardian 
perceptions of 
barriers to 
adherence and 
transplant type 
 
 
 
 
 
 
 
 
 Pediatric and 
adolescent 
solid organ 
transplant 
patients (368 
subject/their 
guardian 
enrolled) 
Multicenter 
study 
 
 
 
 
 
 
 
 Parent and 
adolescent 
medication barrier 
scale (PMBS and 
AMBS) 
  Perceived barriers
were more 
frequently reported 
by guardian of older
recipients compared
to guardian of 
younger recipients, 
related to 
medication 
scheduling and 
medication/disease 
frustration. Pre-
adolescents & 
adolescents scores 
were not statistically
different for any of 
3 factors and there 
were no significant 
interaction between 
age group and organ
for any AMBS 
factors (p > 0.05). 
 Primary analyses 
compared younger 
and older patients 
on each PMBS 
factors using linear 
regression models 
w/multiple 
imputation. The 
difference between 
older recipients and 
guardian 
perceptions of 
  Lack of 
association between 
perceived barriers to 
adherence reported 
in the 
AMBS/PMBS; a 
single blood level of 
primary 
immunosuppressant 
demonstrated the 
limitation of 
adherence measure; 
study cross-sectional 
single snapshot 
design 
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barrier to adherence 
were assessed using 
paired 
t-test on the 
participants PMBS 
& AMBS factor 
scores. Consistency 
between the 
matched PMBS & 
AMBS factor scores
was assessed using 
intraclass 
correlation 
coefficients.  
Secondary analyses 
assessed the 
interaction between 
age group and 
transplant type on 
PMBS & AMBS 
factors using linear 
regression models 
 Association of 3 
identified PMBS 
factors and subject 
age was assessed. 
Secondary analyses 
assessed 
associations 
between PMBS, 
AMBS and patient 
demographic
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McCormick et al. 
(2013). 
Emotional 
Functioning, 
Barriers and 
medication 
Adherence in 
pediatric 
transplant 
recipients 
 
 
 
 
 
 
 
 assessed 
relationship 
among 
internalizing 
symptoms, 
barriers to 
medication 
adherence and 
medication 
adherence in 
adolescents 
with solid 
organ 
transplants 
 Controlled 
cohort Study 
  Level IV 
 Barriers to 
adherence; 
emotional 
functioning and 
medication 
adherence 
 
 
 
 
 
 
 
 
  
 72 adolescents
with solid organ
transplant at 
transplant unit 
 
 
 
 
 
 
 AMBS that 
assessed 
adolescents, 
Adolescents 
emotional 
functioning was 
assessed by three 
domains of 
internalizing 
symptoms: 
depression, anxiety 
and posttraumatic 
stress.  
 Medication 
adherence measure 
(MAM) to assess 
prescribe 
medications 
 MAM has shown 
good convergent 
validity with a 
systematic review of 
adherence, reporting 
that higher rates of 
non-adherence on 
MAM were 
positively correlated 
with rates of non-
adherence calculated 
with electronic 
monitoring 
  Bivariate 
correlations 
revealed 
significant 
relationship 
between 
barriers and 
internalizing 
symptoms of 
depression, 
anxiety and 
posttraumatic 
stress.  
  Barriers 
indicative of 
adaptation to 
the med 
regimen were 
related to 
medication 
adherence and 
mediated the 
relationship 
between 
internalizing 
symptoms and 
med adherence
 Multiple 
mediator 
models were 
tested via 
bootstrapping 
methods
  Due to the cross-
sectional nature or 
research ability to 
draw conclusions 
about causality was 
limited.  
 findings were 
based on individual 
self-report, may 
pose the risk of 
inaccuracy due to 
poor recall or social 
desirability 
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Stirratt et al. 
(2015). 
Self-report 
measures of 
medication 
adherence 
behavior: 
recommendations 
on optimal use 
 
 
 
 
 
 
 
 to review the 
current 
evidence-based 
behind self-
report measures 
of medication 
adherence  
 
  Level VII 
 N/A 
 
 
 
 
 
 
 
 
  
 Patient with 
chronic illness 
Review included
research report 
regarding one or
more 
retrospective 
self-report 
measure of 
medication 
adherence 
behavior, 
published in 
English in the 
last 30 years that
reported 
validation data 
relative to 
clinical outcome
 
 
 
 
 
 
 
 
 
  Rigorous 
development and 
testing of self-
report measures of 
adherence should 
be a research 
priority. There is a 
need to better 
understand how to 
best assess 
adherence among 
patients taking 
multiple 
medications, most 
in patient with 
chronic conditions.
Use of interactive 
voice device (IVR)
or smart phone 
application is an 
important direction
for future research
 
 
 
 
 
 
  Failure to use 
standardized and 
validated self-
report measure is 
a common 
problem in 
health research 
and clinical 
practice 
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Mistry et al. 
(2015) 
Technology-
mediated 
interventions 
(TMI) for 
enhancing 
medication 
adherence 
 
 
 
 
 
 
 
 Assess the 
effects of TMI, 
intended to 
enhance patient 
adherence to 
prescribed 
medications on 
medication 
adherence and 
clinical 
outcomes 
 
  Systematic 
Review of RTCs 
 Level I 
 RTCs grouped 
into 3 categories 
1) education 
and/or 
counselling; 2) 
Self-monitoring 
and/or feedback; 
and 3) electronic 
reminders 
 
 
 
 
 
 
 
  
 38 studies met 
inclusion criteria
 Children and 
adolescents with
chronic illness 
 
 
 
 
 
 Cochrane risk of 
bias tool 
  All analyses 
were conducted 
using SPSS, 
version 20.0 
  50% (19/38) of 
studies found 
improvement in at 
least one measure 
of adherence and 
39% (15/38) of 
studies found 
improvement in at 
least one clinical 
outcome measure 
whereas 36.8% 
(14/38) of studies 
finding 
improvement in 
both adherence and
clinical outcome  
 
 
 
 
  Review 
showed limited 
effective of TMI 
for improving 
patient 
adherence and 
clinical 
outcomes  
  Lack of high-
quality studies. 
Need to future 
reviews 
including quasi-
experimental 
study design in 
addition to RTCs
 E-health and 
use of 
technology to 
improve 
medication 
adherence are in 
their infancy 
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Wu et.al. 
(2018) 
Use of 
smartphone 
application for 
prompting oral 
medication 
adherence 
among 
adolescents and 
young adults 
(AYAs) with 
cancer 
 
 
 
 
 
 
 Explore the 
feasibility and 
acceptability of 
use of a 
smartphone 
medication 
reminder 
application to 
promote 
adherence to 
oral medication 
among AYAs 
 
 
  Controlled 
cohort study 
 Level IV 
 Weekly self-
report 
questionnaires. 
Usage of 
application by 
participants 
and Perceived 
ease of use and 
usefulness of 
application by 
participants 
 
 
 
 
 
 
 
  
 23 AYAs with 
cancer  
 Children’s 
oncology group- 
affiliated 
children’s 
hospital and 
National Cancer 
Institute – 
designated 
comprehensive 
cancer center in 
Salt Lake City, 
UT 
 
 
 
 
 
 Pre/post-test, 
application usage 
was measure by 
1) data download 
from cloud-based 
server; and 11) 
online self-report 
questionnaire 
completed by 
participants each 
week. Six item. 
Cronbach alpha 
for perceived 
ease of use of 
application and 
seven items, 
Cronbach alpha 
for perceived 
usefulness of 
application 
  95 participants 
(58%) indicated 
AYAs took 
medication ~ 76% - 
100% of the time, 
whereas 33 
participants ~ 20% 
indicated taking 
medication ~ 51% - 
75% of the time. 15 
(9%) of participant 
ignored medication 
reminders. 65% of 
participants endorsed 
that application was 
useful.  
 Descriptive 
statistics used for 
demographic 
characteristics. 
Feasibility 
frequencies and 
proportions 
calculated from 
Dosecast usage data 
downloaded and 
descriptive statistics 
used for acceptability
including perceived 
ease of use and 
perceived usefulness 
of the application
  Results 
supports the use 
of electronically 
delivered health 
promotion 
interventions in 
pediatric and 
AYA population 
with cancer 
  Application 
usage data were 
downloaded 
directly from 
application 
server. Study 
sample size was 
small and was 
limited to single 
geographic area 
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Appendix D: Theory to Application Diagram 
 
1. Observational learning/modeling- Participants with their caregiver received four weeks of 
educational session using multicomponent intervention package (MIP). The MIP consists of four 
components including educational and organizational intervention, behavioral modification, 
problem solving skills and monitoring adherence and family functioning. Each component of 
MIP will facilitate learning among participants and will aide to reduce adherence barriers  
2. Self-efficacy- Is the key construct in this model. Each participant and caregiver belief 
about having ability and capacity to accomplish a task that would help them to 
perform behavior to ensure success.  
3. Goals: improve adherence and self-management of treatment regimen  
4. Outcome expectancies- improve adherence and self-management of treatment 
regimen.  
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5. Behavior change- learning behavior modification, problem solving and organizational skill and 
improving family functioning to help promote adherence. Participants and caregiver attended four 
weeks of education session and completed MedActionPlan PRO checklist daily after ingestion of 
medication. 
6. Internal reinforcement- MIP education session provided knowledge and skill for self-
management of treatment regimen  
7. Long-term change- The goals of this project are to improve medication adherence and sustain 
compliance to self-management of their treatment regimen  
8. External reinforcement- MIP education session, healthcare provider and caregiver were able 
inspire positive change, help patient to overcome barrier to change and provide ongoing support 
for emotional well-being. 
 
 
 
 
 
 
 
 
 
 
 
 
 
MEDICATION ADHERENCE   51 
 
 
 
Appendix E: Logic Model 
Rev. 7/09, 1/2015   http://www.uwex.edu/ces/lmcourse/interface/coop_M1_Overview.htm  Logic-Model 
Worksheet content revisions by Lyla Lindholm, Applied to DNP EBP Project. Not to be placed on web for 
public used. For UMKC DNP coursework only 
 
Inquiry, PICOTS:   Among the adolescents and young adults who are recipients of hematopoietic 
stem cell transplant (HSCT), does implementation of a multicomponent intervention package (MIP) 
and smartphone medication reminder application improve adherence and self-management of 
treatment regimen, during a three-month period at a bone marrow transplant outpatient clinic?
Inputs 
 Intervention(s)               
Outputs
Outcomes -- Impact 
 Activities Participation Short Medium Long
Evidence, sub-
topics 
1.Multicomponent 
adherence package 
(MIP) to promote 
adherence  
2. Utilization of 
technology-based 
intervention in 
enhancing treatment 
adherence 
3. Recognizing 
adherence barriers 
to maximize impact 
of MIP 
 
Major Facilitators 
or Contributors 
1.  Patient and 
caregiver readiness 
2.  BMT team 
support including 
midlevel providers, 
staff nurse and 
pharmacists  
3. Mentor support 
 
Major Barriers or 
Challenges 
1.  Funding  
2.  Inadequate 
research staff support  
3.  Clinic time slot 
and room availability 
for education session 
4. Inadequate IT 
support  
 EBP 
Multicomponent 
Intervention 
Package (MIP) & 
smartphone 
medication 
reminder 
application for 
promoting 
adherence 
- Participants and 
caregiver will 
receive ~ 4 weeks 
education session 
MIP.  
- Participants and 
caregiver will 
receive training 
for smartphone 
app usage   
- Participants and 
caregiver will 
complete self-
report 
questionnaire – 
pre and post 
interventions 
 
Major steps of 
the intervention 
(brief phrases) 
1.  APRNs, 
pharmacist and 
will receive 
training to 
implement (MIP)  
2. Schedule 
participants for 
clinic slot for FU 
3. Install 
smartphone apps 
for 
MedActionPlan 
PRO 
The 
participants   
Adolescents 
and young 
adults (12 – 
20yr) with 
hematopoietic 
stem cell 
transplant and 
their 
caregivers 
 
Site 
Children’s 
Mercy 
Hospital, 
outpatient 
clinic  
 
Time Frame  
October to 
January 2018 
 
Consent or 
assent: Yes 
for 
participation 
in study  
 
Other 
person(s) 
collecting 
data: NO 
  
 
Others 
directly 
involved in 
consent        
Yes 
 (Completed 
during DNP 
Project)  
 
Outcome(s) to 
be measured 
Adherence 
from baseline 
to post-
intervention 
and from 
baseline to 1 
month follow 
up  
 
 Measurement 
tool 
1.  
PMBS/AMBS 
for pre- and 
post- 
interventions 
self-report 
questionnaire 
2.  Usage and 
responses of 
smartphone 
application 
 
Statistical 
analysis to be 
used 
1.  IBM’s SPSS 
version 22 
statistics.  
2. A paired two 
tailed  
 
 
(after student 
DNP)  
 
Outcomes to be 
measured  
Utilize MIP as 
standard of care 
to promote 
medication 
adherence in 
AYAs with  
 
 
 
 
 
 
 
 
 
 
 
(after student 
DNP) 
 
Outcomes that 
are potentials  
Decrease in 
transplant related 
complication and 
improve quality 
 of life 
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Appendix F: Cost Table 
Student Investigator Project Start Date- 01/2019   
Type of Grant-  None   
Item Cost Note 
Rukhsana Rahmetulla- 
Student Investigator Salary 
$0.00 Student Investigator- 
Uncompensated 
BMT Outpatient NPs : 2 $0.00 Student Investigator- 
Uncompensated 
BMT Pharmacist: 1 $0.00 Student Investigator- 
Uncompensated 
Project clinical expert $0.00 Student Investigator- 
Uncompensated 
MedActionPlan PRO 
checklist   
$0.00 Printed updated checklist was 
provided at each session 
 
Supplies: 
MedActionPlan PRO 
checklist for participants 
Education handouts for 
project team and participants  
Pill boxes 
 
$0.00 
 
$10 – 15/participants 
Received donation 
 
 
 
Provided by project team 
Total $ 20 – 30 for both 
participants 
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Appendix G: Project Timeline Flow Graphic 
 
2014‐
2016
Research topic 
of interest for 
possible EBP 
project
Collect current 
literature on 
EBP topic
2016‐
2017
Specify project 
PICOTS inquiry
Select theories 
to support 
project 
implementation
2017‐
2018
Receive 
approval for site 
implementation
Finalize step‐by‐
step 
intervention 
process
2018‐
2019
Implement EBP 
project
Collect and 
analyze results
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Appendix H: Intervention Flow Diagram 
 
 
 
 
 
 
 
 
 
 
Step 1: Study team training and recruitment 
Outpatient bone marrow transplant (BMT) nurse practitioners and pharmacist received  2 sessions each 90 minutes by licensed 
psychologist (clinical expert) for Multicomponent Interventions Package (MIP) for standard implementation 
Post-transplant recipients who are 12 – 20 years with their care giver were approached for project participation (BMT 
Outpatient APN and pharmacist), during parent care status ~ 3-4 days prior to their discharge from bone marrow transplant 
inpatient unit at local hospital.  
Step 2: Scheduling study participants with caregiver  
Study participants and their care givers were scheduled for MIP (four weekly in person sessions) with regular outpatient clinic 
visits.  
Step 3: Baseline data collection
 Baseline assessment (pre-intervention) using Adolescents Medication Barrier Scale (AMBS) and Parent Medication 
Barrier Scale (PMBS) 
 Med Rec (BMT Pharmacist/APN) using MedActionPlan PRO checklist and questionnaire self-report adherence 
behavior  
Step 4: Weekly Adherence assessment (Outpatient visit) 
 Med Rec (BMT Pharmacist/APN) using MedActionPlan PRO checklist and questionnaire self-report adherence 
behavior
Step 5: Education sessions and assessment 
 MIP sessions every week x 4 weeks, using MedActionPlan PRO checklist with clinic visits, questionnaire self-report 
adherence behavior  
 At 5th week participants to complete post-intervention Adolescents Medication Barrier Scale (AMBS), Parent 
Medication Barrier Scale (PMBS) as post intervention self-report  and adherence intervention satisfaction survey 
(Parent/caregiver and patient) 
Step 6: Data collection, analysis and evaluation 
 Data Collection and analysis: Collect data from pre and post intervention using PMBA and AMBS average, usage of 
MedActionPlan PRO checklist with clinic visits, questionnaire self-report adherence behavior and adherence 
intervention satisfaction survey (Parent/caregiver and patient) 
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Appendix I: Theory to Application Diagram 
Change Curve Model 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Melnyk, D.M. & Fineout-Overholt, E. (2015). Evidence-based practice in nursing 
and healthcare: a guide to best practice (3rd ed). Philadelphia: Wolters 
Kluwer/Lippincott Williams & Wilkins. 
 
 
 
Stage 1: Stagnation: Medication adherence is a complex human 
behavior. The recommended adherence to oral medication is 80% 
to 95%, however it is estimated 27% to 74% in AYAs, resulting in 
suboptimal clinical outcomes and increase in healthcare 
i
Stage 4: Determination: Evaluate adherence and ability to self-
manage treatment regimen, and change in adherence. Feasibility 
and acceptability of MIP and MedActionPlan PRO app/checklist 
Stage 2: Preparation: Collect specific information for adherence 
promoting interventions including multicomponent Intervention 
Package (MIP) and technology-based intervention. Identify setting 
for intervention
Stage 3: Implementation: Training for projet team for MIP at least 
a month prior to launch of study – 4 weekly session 120 minutes 
long with clinical expert. MedActionPlan PRO application 
training.  Follow up weekly visit for intervention x 4 weeks 
Stage 5: Fruition: Continue assess adherence during outpatient 
follow up visit after completion of project 
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Appendix J: Measurement Tool 
  Add the key reliability content to the body of the paper content.  
 
Outcome Instrument or 
Source 
Validity Reliability Permission 
for Use 
#1 (a) 
Barriers to 
adherence 
 AMBS & 
PMBS 
PMBS is designed 
to assess 
adolescent and 
parent perceived 
barriers to their 
child’s medication 
taking whereas 
AMBS assesses 
adolescent 
perceived barriers 
to their prescribed 
medication taking.  
Both are validated 
tools for assess 
barriers to 
medication 
adherence
PMBS consists 
16 items with 
max score of 80. 
Cronbach α 0.87 
indicates strong 
internal 
consistency. 
AMBS consists 
17 items with a 
max score of 85.  
Cronbach α 0.86 
indicates strong 
internal 
consistency. 
Permission 
received 
via email  
#2 
MedActionPl
an PRO  
application 
MedActionPla
n PRO 
checklist 
N/A N/A N/A 
# 3 
Multicompon
ent 
adherence 
interventions 
 Intervention’s 
impact 
N/A N/A N/A 
# 4 
Self-
Reported 
adherence 
behaviors 
Questionnaire N/A N/A N/A 
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Appendix K: Permission for Tool 
Rukhsana, 
 
Thanks for your interest! 
 
Yes, you have permission to use! Attached are the measures and scoring directions.  
 
Thanks!  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
